End-of-day quote
Other stock markets
|
||
- GBX | - |
02:30pm | NOVARTIS AG : JP Morgan gives a Neutral rating | ZD |
01:51pm | NOVARTIS AG : Barclays keeps a Sell rating | ZD |
Financials (USD)
Sales 2024 * | 48.65B | Sales 2025 * | 49.87B | Capitalization | 210B |
---|---|---|---|---|---|
Net income 2024 * | 9.52B | Net income 2025 * | 11.58B | EV / Sales 2024 * | 4.54 x |
Net Debt 2024 * | 10.94B | Net Debt 2025 * | 10.14B | EV / Sales 2025 * | 4.41 x |
P/E ratio 2024 * |
19.4
x | P/E ratio 2025 * |
16.7
x | Employees | - |
Yield 2024 * |
3.79% | Yield 2025 * |
3.91% | Free-Float | 81.95% |
Latest transcript on NOVARTIS
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 |
1st Jan change | Capi. | |
---|---|---|
+25.46% | 659B | |
+26.82% | 557B | |
-4.86% | 359B | |
+16.44% | 322B | |
+8.34% | 297B | |
+6.23% | 215B | |
-6.13% | 200B | |
-8.79% | 149B | |
-5.59% | 146B |
- Stock Market
- Equities
- NOVN Stock
- 0HKE Stock